Immunocore Holdings PLC
NASDAQ:IMCR
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
30
75.36
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one IMCR stock under the Base Case scenario is 120.56 USD. Compared to the current market price of 33.75 USD, Immunocore Holdings PLC is Undervalued by 72%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Immunocore Holdings PLC
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for IMCR cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Immunocore Holdings PLC
Balance Sheet Decomposition
Immunocore Holdings PLC
Current Assets | 956.9m |
Cash & Short-Term Investments | 859.6m |
Receivables | 60.2m |
Other Current Assets | 37m |
Non-Current Assets | 66.5m |
Long-Term Investments | 16.3m |
PP&E | 40.1m |
Other Non-Current Assets | 10.1m |
Current Liabilities | 185.1m |
Accounts Payable | 19.9m |
Accrued Liabilities | 165.1m |
Non-Current Liabilities | 479.1m |
Long-Term Debt | 438.1m |
Other Non-Current Liabilities | 41m |
Earnings Waterfall
Immunocore Holdings PLC
Revenue
|
460.7m
GBP
|
Cost of Revenue
|
-3.3m
GBP
|
Gross Profit
|
457.4m
GBP
|
Operating Expenses
|
-560.4m
GBP
|
Operating Income
|
-103m
GBP
|
Other Expenses
|
14.1m
GBP
|
Net Income
|
-88.9m
GBP
|
Free Cash Flow Analysis
Immunocore Holdings PLC
GBP | |
Free Cash Flow | GBP |
In the first half of 2024, net sales of KIMMTRAK reached $146 million, a 34% increase year-over-year. The second quarter alone brought in $75.3 million, mainly due to an 11% growth in the U.S., achieving a 65% market share. KIMMTRAK is now available in 19 countries, with further launches in Poland and Sweden anticipated. Despite a challenging reimbursement environment in Europe, global revenue continues to rise. The company is progressing with Phase III trials for KIMMTRAK in advanced cutaneous melanoma, which could extend its benefits to up to 6,000 patients.
What is Earnings Call?
IMCR Profitability Score
Profitability Due Diligence
Immunocore Holdings PLC's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
Score
Immunocore Holdings PLC's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
IMCR Solvency Score
Solvency Due Diligence
Immunocore Holdings PLC's solvency score is 41/100. The higher the solvency score, the more solvent the company is.
Score
Immunocore Holdings PLC's solvency score is 41/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IMCR Price Targets Summary
Immunocore Holdings PLC
According to Wall Street analysts, the average 1-year price target for IMCR is 82.4 USD with a low forecast of 66.66 USD and a high forecast of 105 USD.
Dividends
Current shareholder yield for IMCR is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
IMCR Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Immunocore Holdings Plc operates as a holding company. The company is headquartered in Abingdon, Oxfordshire and currently employs 324 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in the development of TCR bispecific immunotherapies called Immune mobilizing monoclonal TCRs Against X disease (ImmTAX) designed to treat diseases, including cancer, infectious and autoimmune. The firm is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. The Company’s pipeline is leveraging ImmTAX platform within three therapeutic areas: oncology, infectious disease and autoimmune disease. Its product candidate KIMMTRAK is used for positive adult patients with unresectable or metastatic uveal melanoma (mUM) having demonstrated in Phase III clinical trial.
Contact
IPO
Employees
Officers
The intrinsic value of one IMCR stock under the Base Case scenario is 120.56 USD.
Compared to the current market price of 33.75 USD, Immunocore Holdings PLC is Undervalued by 72%.